Innate Immunotherapeutics Limited announced that Dr. Warwick Tong has been appointed Chairman of the Board of Directors. Warwick brings 20 years of international clinical, commercial, and drug development leadership experience in both the pharmaceutical and biotechnology industries. Warwick was appointed as a Director of Innate on May 4, 2018, following the company's successful acquisition of Amplia Therapeutics Pty Ltd. (Amplia) and currently serves as a member of the company's Audit and Risk Committee. Previously he was the Cancer Research UK (CRUK) appointed director to the Board of Amplia.